Overall concluding remarks
OECD countries (including the US) continue to be aware of rising cost issues and are experimenting with policy changes
Strong emphasis on the demand-side
Continued emphasis on the supply-side; in some cases, increased emphasis on S-S
Shift towards aggressive bargaining rather than command-and-control
Emphasis on policy assessment
Lessons from other OECD countries may include:
- Using economic evidence more intensively
- Managing “price” better or differently
- Aggressively managing formularies
- Reference pricing
- Physician incentives
- Return on capital formulae for drug procurement
- More aggressive discounts required for early launch